Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
81.1M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
37.8M
-
Shares change
-
+9.43M
-
Total reported value, excl. options
-
$775M
-
Value change
-
+$210M
-
Put/Call ratio
-
0.26
-
Number of buys
-
78
-
Number of sells
-
-24
-
Price
-
$20.51
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) as of Q3 2022
120 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share as of Q3 2022.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.8M shares
of 81.1M outstanding shares and own 46.56% of the company stock.
Largest 10 shareholders include COMMODORE CAPITAL LP (2.7M shares), VR Adviser, LLC (2.13M shares), BlackRock Inc. (1.98M shares), Deep Track Capital, LP (1.97M shares), VANGUARD GROUP INC (1.86M shares), BVF INC/IL (1.74M shares), Vivo Capital, LLC (1.66M shares), Paradigm Biocapital Advisors LP (1.64M shares), Fairmount Funds Management LLC (1.37M shares), and CITADEL ADVISORS LLC (1.36M shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.